



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

HCPWP – Healthcare Professionals' Working Party

Nomination of observers

Presented by: Ivana Silva
Public Information and Stakeholder Networking/ Medical Information

An agency of the European Union





Responsibilities of observers

- Represent the HCPWP in EMA groups, as appropriate (rotation among observer/ alternate is possible)
- Shall ensure that the views expressed (if any) are those of the HCPWP
- Report to the HCPWP plenary, as necessary

Expression of interest

- Expressions of interest to be received by EMA in writing
- HCWP co-chairs and secretariat will assess expressions of interest and agree on the observer or
- May need to go back to the Working Party for a decision



Nomination of observers

The European Medicines Agency Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (more commonly known as the **Patients' and Consumers' Working Party** or **PCWP**) provides recommendations to the European Medicines Agency and its human scientific committees on all matters of interest to patients in relation to medicinal products.

- Observer nominated for a term of three years






Nomination of observers

- The **European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP)** is a collaborative scientific network coordinated by the European Medicines Agency to strengthen the post-authorisation monitoring of medicinal products in Europe
- Brings together over 170 academic and hospital-based research centres, providers of healthcare data and specialised networks across Europe



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH





Nomination of observers

The **European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA)** is a network of research networks, investigators and centres with recognised expertise in performing clinical studies in children.

Enpr-EMA's objectives include:

- Fostering high-quality, ethical research on the quality, safety and efficacy of medicines for use in children;
- Enabling collaboration between networks and stakeholders;
- Coordinating studies relating to paediatric medicines and avoid unnecessary testing in children;



**Better medicines for
children**

